With one in three women affected by conditions stemming from poor ovarian health, the status quo of treatment, relying heavily on hormonal interventions established over 50 years ago, presents a glaring concern. Beyond the immediate discomfort of often debilitating symptoms, the repercussions extend to serious health implications due to the ovary's pivotal role in overall endocrine function. Amidst this landscape, Celmatix Inc. emerges as a beacon of innovation in women's health biotechnology, dedicated to unraveling the intricacies of ovarian biology.

Through pioneering research and groundbreaking advancements, Celmatix is leading the charge against ovarian senescence, offering hope to women worldwide. At the core of its mission lies the transformative "pipeline-in-a-pill" AMHR2 program, poised to redefine treatment paradigms for ovarian-related conditions. Bolstered by strategic collaborations with industry leaders and fueled by its proprietary multi-omic ovarian health platform, Celmatix is committed to addressing critical unmet needs and ushering in a new era of women's health therapeutics. Join us as we embark on a journey to decode ovarian function and revolutionize the landscape of women's health.

Celmatix's Groundbreaking Discovery Program: Pioneering Advancements in Ovarian Health

Celmatix proudly presents its revolutionary discovery program, boasting the most extensive structured dataset on ovarian health and outcomes globally. This proprietary resource stands poised to shape the next decade of breakthroughs in the field, fueling both internally retained and partnered drug initiatives.

Industry-Leading Components

1. Proprietary Cohorts

Celmatix's repository comprises meticulously curated cohorts, encompassing treatment histories, medical records, genomic insights, and biological samples from a staggering pool of over half a million individuals. This rich repository forms the foundation for in-depth analysis and exploration, driving forward our understanding of ovarian health.

2. Proprietary Annotations

Delving deeper into structured reproductive data, Celmatix's program incorporates insights from published studies, spanning human and mouse research. These annotations facilitate the construction of clinical validity scores and reproductive phenotype classification data, providing invaluable insights into the complexities of ovarian health.

3. Proprietary Research Tools

Facilitating seamless navigation through the vast landscape of ovarian research, Celmatix's arsenal includes a cutting-edge annotation platform. This tool covers a comprehensive array of published studies, constantly updated through advanced NLP neural network models. By automatically discerning the type and relevance of new studies, this platform ensures that Celmatix remains at the forefront of emerging research trends.

4. Licensed Cohorts

Further enriching its dataset, Celmatix incorporates licensed cohorts featuring genotyping and whole exome sequencing data. Paired with detailed diagnoses, medical histories, and lifestyle information, these cohorts provide unparalleled depth and breadth of insights into ovarian health and its associated conditions.

In essence, Celmatix's discovery program represents a transformative leap forward in our collective understanding of ovarian health. With its vast repository and cutting-edge tools, Celmatix is poised to drive groundbreaking advancements and unlock new avenues for therapeutic intervention in this critical field.

Celmatix's Dynamic Partnerships: Advancing Women's Health Therapeutics

Fostering Cohort Studies for Comprehensive Insights

In a collaborative effort known as the Personalized Reproductive Medicine initiative, Celmatix joins forces with fifteen esteemed reproductive health centers across the United States. This strategic partnership aims to amass a wealth of biological samples, complemented by comprehensive medical and clinical histories, including data on reproductive partners. Through this collective endeavor, Celmatix endeavors to deepen our understanding of reproductive health and pave the way for targeted therapeutic interventions.

Driving Preclinical Discovery & Development

Celmatix embarks on a transformative journey in partnership with Evotec, a collaboration marked by long-term research commitments and strategic investment to fuel mutual growth. Together, Celmatix and Evotec are dedicated to identifying and validating therapeutic targets for conditions characterized by significant unmet needs, including endometriosis, Polycystic Ovary Syndrome (PCOS), and ovarian senescence. Through this synergistic partnership, Celmatix aims to accelerate the translation of scientific discoveries into impactful therapeutic solutions.

Enabling Collaborative Discovery, Development, & Commercialization

In a multifaceted collaboration with Evotec and Bayer, Celmatix takes strides towards addressing the challenges posed by Polycystic Ovary Syndrome (PCOS). Leveraging Celmatix's expertise in identifying novel PCOS targets, Bayer is poised to lead the charge in bringing new treatments to women grappling with this debilitating disease. This comprehensive five-year collaboration encompasses the entire spectrum of discovery, development, and commercialization efforts, with the collective goal of delivering multiple clinical candidates to market.

Revolutionizing Contraceptive Discovery & Development

Recognizing the urgent need for improved contraceptive options, Celmatix embarks on a transformative journey with support from the Bill & Melinda Gates Foundation. Through this strategic partnership, Celmatix is dedicated to identifying novel targets for next-generation female contraceptive drug discovery. With a focus on addressing the needs of over 225 million women in low and middle-income countries, Celmatix's collaborative efforts promise to revolutionize contraceptive care and empower women worldwide.Top of Form

The Stalwart Leader at the Helm of Celmatix

Dr. Piraye Yurttas Beim, PhD is the Founder & CEO of Celmatix. Dr. Beim has been innovating in women's health for over 20 years. During her PhD work at Cornell (Weill, NYC) and Memorial Sloan Kettering Cancer Center in the early 2000s, she was on the front lines of precision medicine in oncology and saw the transformational impact of genomics on drug target selection and biomarker-based patient stratification on the emergence of targeted therapies and the corresponding improvement in the standard of care. After completing her post-doc focused on mammalian reproduction at the University of Cambridge (UK), she was inspired to found Celmatix. The vision of the company since its founding has been to accelerate precision medicine innovations in women’s health.

Under Dr. Beim's leadership, Celmatix pioneered breakthroughs in decoding the genomic drivers of ovarian function and health, and led the development of Celmatix’s ovarian health platform, an ambitious, decade-long, multi-omics initiative that has yielded unprecedented insight into the key molecular drivers of ovarian function and reproductive health conditions. Dr. Beim has also been a primary inventor of most of Celmatix’s innovations, including the AMHR2 agonist and follow-on AMHR2 antagonist programs, each a first-in-class approach to the modulation of ovarian folliculogenesis.

In addition to leading the development of novel therapeutics, she has also developed diagnostics and digital health products in the women’s health field. Dr. Beim has also been widely recognized as a business leader. She is a member of the Aspen Global Leadership Network, was named to Crain’s 40 Under 40 as well as its Notable Women in Tech, Goldman Sachs's Most Intriguing Entrepreneurs, Top 15 founders disrupting their industries by Fortune, and Rock Health's Disruptive Founder of the Year.

“Celmatix is addressing areas of high unmet need by developing the next generation of interventions and pioneering advancements in ovarian health.”